Educational sessions begm on October 6th in a joint session with the ASUTS (see below). An advanced educational session will be held on October 7th. The scientific sessions begin on October 8th, continuing through October 10th.
1974 Abstracts American Society of Ultrasound Technical Specialists
โ Scribed by Nan Adams; John H. K. Vogel; Caroline F. Anderson; James J. Corrigan; Harlan R. Giles; David B. Rosenberg; Ronald E. Balint; Ronald E. Balint; Ronald E. Balint; Janet E. Bolin; Melanie Stipes; Ernest N. Carlsen; Betty Chilcote; Wayne Chilcote; Betty Chilcote; Wayne Chilcote; Carolyn Gegor; Fred Gentry; T. J. Brickner Jr.; R. G. Ellis; David V. Eakin; John C. Hobbins; Dolores May; Mazie M. Kopta; Joan Korfhagen; Richard A. Meyer; Samuel Kaplan; Denise Moulton; Marveen Naglish; J. A. Persaud; R. L. Schuld; D. R. Boughner; Betty J. Phillips; Vincent E. Friedewald Jr.; H. W. Poehlmann; R. E. Brown; Cynthia Quinter; David B. Rosenberg; Harlan R. Giles; Caroline F. Anderson; Sally Smith; Marcia Murray; Elvira Vinson; Michael Shaub; Robert L. Wilson; Diana Swan; Richard Leung; Roger J. Cunningham; Frank W. Kroetz; Milo N. Webber; Francine Aguilar; Michael Cragin; J. W. Willard; W. McKinney; W. H. Boyce; Edwina E. Wilson; G. Wodraska; M. Tenner
- Publisher
- John Wiley and Sons
- Year
- 1974
- Tongue
- English
- Weight
- 654 KB
- Volume
- 2
- Category
- Article
- ISSN
- 0091-2751
No coin nor oath required. For personal study only.
โฆ Synopsis
Abstract
We are printing the ASUTS abstracts presented at their meeting in Seattle, 5 October 1974. Because of a change in policy in the convention office at Seattle, these were not published in the September issue.
๐ SIMILAR VOLUMES
## Abstract The histories of the American Society for Apheresis (ASFA) and the Society for Hemapheresis Specialists (SHS) are intimately intertwined with Francis S Morrison, MD. Because many of the relevant historical events are not recorded as written documents, it is useful to revisit them via th
INTRODUCTION: Targeted drug therapy is the Holy Grail of oncology. Through the understanding of key molecular pathways involved in tumor growth, specific inhibitors can be designed to inactivate these pathways, thereby maximizing therapeutic response. One of the most compelling examples of successfu